Research and Markets: Pre-Clinical Stage Partnering Agreements in
Biopharma Reveals How and Why Companies Enter Pre-Clinical Stage
Licensing/Business Development
(M2 PressWIRE Via Acquire Media NewsEdge)
RDATE:15102008
Dublin - Research and Markets
(http://www.researchandmarkets.com/research/6d31b9/preclinical_stage)
has announced the addition of the "Pre-clinical Stage Partnering
Agreements in Biopharma" report to their offering.
The Pre-clinical Stage Partnering Agreements in Biopharma report
details an understanding and analysis of how and why companies enter
pre-clinical stage licensing/business development and other forms of
partnering arrangement.
The report provides a detailed understanding and analysis of how and
why companies enter pre-clinical stage licensing/business development
and other forms of partnering arrangement.
The focus of the report is on partnerships for pre-clinical stage
compounds where partners have joined forces to exploit these early
stage opportunities. This is an early stage of partnering undertaken by
commercial entities with the objective of utilizing lead molecules and
pre-clinical compounds to progress into clinical stage pipeline
development.
The report provides access to average pre-clinical stage deal payment
terms as announced between the parties. This data provides useful
insight into the average and range of payments for upfront, milestone
and royalty payments agreed for pre-clinical stage deals.
This report contains over 800 links to online copies of actual
pre-clinical stage contract documents as submitted to the Securities
Exchange Commission by biopharma companies and their partners.
Key benefits
Pre-clinical Stage Partnering Agreements in Biopharma provides the
reader with the following key benefits:
- In-depth understanding of pre-clinical stage partnering deal trends
since 2000
- Analysis of the structure of pre-clinical stage partnering agreements
with numerous real life case studies
- Comprehensive access to over 800 actual pre-clinical stage partnering
contracts entered into by the world s biopharma companies*
- Detailed access to actual pre-clinical stage partnering contracts
enter into by the leading fifty bigpharma companies*
- Insight into the payment and deal terms included in a pre-clinical
stage partnering agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal
terms for partner companies
*Subject to being published via regulatory requirements of the
Securities Exchange Commission.
Report scope
Pre-clinical Stage Partnering Agreements in Biopharma is intended to
provide the reader with an in-depth understanding of the pre-clinical
stage partnering trends and structure of deals entered into by leading
biopharma companies worldwide.
Pre-clinical Stage Partnering Agreements in Biopharma includes:
- Trends in pre-clinical stage partnering dealmaking in the biopharma
industry since 2000
- Analysis of pre-clinical stage partnering deal structure
- Average payment terms for pre-clinical stage deals
- Case studies of real-life pre-clinical stage partnering deals
- Access to over 1000 pre-clinical stage partnering contract documents
- The leading pre-clinical stage partnering deals by value since 2000
- Most active pre-clinical stage partnering dealmakers since 2000
- The leading pre-clinical stage partnering resources
Executive Summary:
The initial chapters of this report provide an orientation of
pre-clinical stage dealmaking and business activities. Chapter 1
provides an introduction to the report, whilst chapter 2 provides an
analysis of the trends in pre-clinical stage partnering as well as a
discussion on the merits and attributes of dealmaking at the
pre-clinical stage of development.
Chapter 3 provides an overview of the structure of pre-clinical stage
partnering deal contracts. The chapter includes numerous case studies
to enable understanding of pre-clinical stage partnering deals.
Chapter 4 provides a review of the leading pre-clinical stage
partnering deals since 2000. Deals are listed by headline value, signed
by bigpharma, most active bigpharma, and most active of all biopharma
companies. Where the deal has an agreement contract published at the
SEC a link provides online access to the contract.
Chapter 5 provides a comprehensive listing of the top 50 bigpharma
companies with a brief summary followed by a comprehensive listing of
pre-clinical stage contract documents available in the public domain.
Each deal title links via Weblink to an online version of the actual
contract document, providing easy access to each contract document on
demand.
Chapter 6 provides a comprehensive listing of all pre-clinical stage
agreement contracts since 2003 available in the public domain,
respectively. Each chapter is organized by A-Z, therapeutic area, and
deal type. Each deal title links via Weblink to an online version of
the actual contract document, providing easy access to each contract
document on demand.
The report also includes numerous tables and figures that illustrate
the trends and activities in pre-clinical stage dealmaking since 2000.
In conclusion, this report provides everything a prospective dealmaker
needs to know about pre-clinical stage partnering, enabling thorough
learning, education and due diligence prior and during the pre-clinical
stage dealmaking process.
In Pre-clinical Stage Partnering Agreements in Biopharma, the available
contracts are listed by:
- A-Z
- Headline value
- Therapeutic area
- Deal type
Each deal title links via Weblink to an online version of the actual
contract document, providing easy access to each contract document on
demand.
The Pre-clinical Stage Partnering Agreements in Biopharma report
provides comprehensive access to available contract documents for over
800 pre-clinical stage partnering deals. Analyzing actual contract
agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How do milestone align with clinical stage development phases?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or
deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Executive Summary
Chapter 1 Introduction
Chapter 2 Trends in pre-clinical stage dealmaking
2.1. Introduction
2.2. Difference between lead and pre-clinical compound deals
2.2.1. Trends in pre-clinical stage deals since 2000
2.2.2. Attributes of pre-clinical stage deals
2.3. Reasons for entering into pre-clinical stage partnering deals
2.3.1. Licensors reasons for entering pre-clinical stage deals
2.3.2. Licensees reasons for entering pre-clinical stage deals
2.4. The future of pre-cliincal stage partnering deals
Chapter 3 Overview of pre-clinical stage deal structure
3.1. Introduction 3.2. The anatomy of a pre-clinical stage deal
3.2.1. Example pre-clinical stage agreements
3.2.1.a. Case study 1: Tracon Cell Matrix Cancervax March 2007
3.2.1.b. Case study 2: Pfizer InSite Vision February 2007
Chapter 4 Leading pre-clinical stage deals
4.1. Introduction
4.2. Top pre-clinical stage deals by value
4.3. Top pre-clinical stage deals signed by bigpharma
6.3. By therapy area Accident/Hospital/Trauma Blood/Lymphatic System
Cardiovascular Central nervous System Dermatology Gastrointestinal
Genetic Genitourinary Autoimmune/Inflammatory Infection Metabolism
Musculoskeletal Oncology Respiratory Sensory Organ / Oral Health
Delivery
6.4. By deal type Collaborative R&D Co-development Co-marketing
Co-promotion Development Distribution Joint venture Licensing M&A
Manufacturing Marketing Promotion Research Supply
CONTACT: Laura Wood, Senior Manager, Research and Markets
Fax: +1 646 607 1907 (US)
Fax: +353 1 481 1716 (Rest of World)
e-mail: press@researchandmarkets.com
((M2 Communications Ltd disclaims all liability for information
provided within M2 PressWIRE. Data supplied by named party/parties.
Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to
info@m2.com)).
INDUSTRIES
INDUSTRIES
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO East, February 2-4, 2009. Miami, Florida.
